Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study

BACKGROUND: Recent vasodilating drugs have improved prognosis of Pulmonary arterial hypertension (PAH). Some reports describe the merits of combination therapies for PAH, and this study evaluated the efficacy and safety of phosphodiesterase type 5 inhibitors (PDE5i) combination therapy, using silden...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimura, Mai, Tamura, Yuichi, Takei, Makoto, Yamamoto, Tsunehisa, Ono, Tomohiko, Fujita, Jun, Kataoka, Masaharu, Kuwana, Masataka, Satoh, Toru, Fukuda, Keiichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4436029/
https://www.ncbi.nlm.nih.gov/pubmed/25971443
http://dx.doi.org/10.1186/s12890-015-0037-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4436029/
https://www.ncbi.nlm.nih.gov/pubmed/25971443
http://dx.doi.org/10.1186/s12890-015-0037-8

Ejemplares similares